title: Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent.
abstract: In this study, we examined the mitogen-activated protein kinase (MAPK) cascade in micrometastatic cell lines generated from rib bone marrow (RBM) of patients undergoing resection of esophagogastric malignancies. The molecular mechanism(s) involved in esophagogastric MAPK activation have not previously been investigated. Constitutive activation of both ERK1 and -2 isoforms was evident in each of the five RBM cell lines. Elk-1, a transcription factor activated by the ERK1/2 pathway was also found to be constitutively activated. Cell lines generated from metastases of involved lymph nodes (OC2) and ascites (OC1) of patients with esophageal cancer do not display, however, hyperphosphorylation of ERK1/2. Constitutive RBM ERK1/2 activation is protein kinase C and phosphatidylinositol 3-kinase dependent. Surprisingly, constitutive ERK1/2 activation is MEK-independent. Pharmacological inhibition of MEK with two specific inhibitors, PD 98059 and U0126, were both ineffective in blocking ERK activation. Similarly, the use of a dominant negative MEK mutant was without effect. Interestingly, experiments overexpressing two different dominant negative Pak1 mutants significantly reduced RBM ERK1/2 activation, albeit not to the same extent for all cell lines. We also examined the role of three different phosphatases, PAC1, MKP-1, and -2. While RBM ERK1/2 activation was found to be PAC1- and MKP-2-independent, surprisingly, MKP-1 was down-regulated in all five RBM cell lines. In conclusion, we provide evidence for the first time for a MEK-independent constitutive ERK1/2 activation pathway in esophagogastric RBM cell lines. These findings have important implications for drug treatment strategies which currently target MEK in other forms of cancer.
authors: Cork Cancer Research Center, National University of Ireland, Cork, Ireland.
authors: O P
authors: OP
authors: Barry
authors: B
authors: B
authors: Mullan
authors: D
authors: D
authors: Sheehan
authors: M G
authors: MG
authors: Kazanietz
authors: F
authors: F
authors: Shanahan
authors: J K
authors: JK
authors: Collins
authors: G C
authors: GC
authors: O'Sullivan
mesh_terms: D001483:Base Sequence; D019046:Bone Marrow Neoplasms / Q000201:enzymology / Q000473:pathology / Q000556:secondary*; D017931:DNA Primers; D004789:Enzyme Activation; D004938:Esophageal Neoplasms / Q000473:pathology; D004947:Esophagus; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D012272:Ribs / Q000201:enzymology*; D013270:Stomach; D013274:Stomach Neoplasms / Q000473:pathology
chemical_list: D017931:DNA Primers; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases